Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C
Related Experiment Video
Updated: Apr 6, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Juan A Pineda1, Rocio Núñez-Torres1, Francisco Téllez2
1Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Avda. de Bellavista s/n, 41014 Sevilla, Spain.
Insights
Hepatitis C virus (HCV) reinfection is low in HIV-coinfected patients who achieved sustained virological response. Low-risk behavior contributes to this, supporting HCV treatment in people who inject drugs.
Area of Science:
- Infectious Diseases
- Hepatology
- Virology
Background:
- Hepatitis C virus (HCV) infection is a significant concern in patients coinfected with HIV.
- Achieving sustained virological response (SVR) through therapy is crucial for managing chronic hepatitis C.
- Understanding reinfection rates is vital for long-term patient management and treatment strategies.
Purpose of the Study:
- To determine the incidence of HCV reinfection in individuals coinfected with HIV who previously achieved SVR.
- To identify factors associated with HCV reinfection in this population.
- To inform treatment guidelines for HCV in HIV-coinfected patients, particularly people who inject drugs (PWID).
Main Methods:
- Analysis of 84 HIV-infected patients with prior SVR after HCV treatment.
- Regular HCV RNA monitoring over a median follow-up of 34 months.
- Assessment of risk behaviors, including drug use and sexual practices, during follow-up.
Main Results:
- Four out of 84 patients (4.76%) experienced HCV reinfection, with an incidence of 1.21 per 100 person-years.
- Reinfected patients maintained risk factors for HCV transmission.
- HCV genotype switching occurred in three cases, and one case suggested sexual transmission.
Conclusions:
- The incidence of HCV reinfection after successful therapy in HIV-coinfected patients is low.
- Low frequency of risk behaviors is the primary factor limiting reinfection rates.
- The risk of reinfection should not deter the treatment of HCV with direct-acting antivirals, even in PWID.
Objectives:
To assess the incidence of hepatitis C virus (HCV) reinfections after therapy-induced clearance in HIV-coinfected patients with prior chronic hepatitis C.
Methods:
Eighty-four HIV-infected subjects, who had previously achieved sustained virological response (SVR) after being treated of chronic hepatitis C, were analyzed. In all of them, at least yearly HCV RNA determinations were carried out during a median (range) of 34 (12-146) months.
Results:
Seventy-two (86%) subjects had been people who inject drugs (PWID), of whom 11 (15%) continued to use snorted or injected drugs during the follow-up. Four (4.76%) patients showed HCV reinfection (incidence 1.21 [95% confidence interval: 0.3-3.09] cases per 100 person-years). These patients maintained risk factors for HCV infection. In three cases, HCV genotype switched. Phylogenetic analysis of the remaining case suggested reinfection from his sexual partner.
Conclusion:
The incidence of HCV reinfection in the overall population of HIV-coinfected patients who achieved SVR after being treated against chronic hepatitis C is low. A low frequency of risk behavior is the main factor accounting for this modest rate of reinfection. The possibility of reinfection should not be considered a reason against treatment of HCV infection with direct acting antivirals in PWID.
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Cytomegalovirus Disease
Size and Structure of Viral Genomes
Viruses with RNA Genomes

